GlassScriptPhysician profile
William Joseph Morris
NPI 1912935453
$5,672.98
in general payments reported to CMS, 2019-2025
33 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $1,116 · 2021: $851 · 2022: $1,082 · 2023: $448 · 2024: $305 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $924.95 | 2019-2025 | |
| Lilly USA, LLC | $803.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $642.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $580.46 | 2019-2025 | |
| Amarin Pharma, INC. | $407.36 | 2019-2020 | |
| Novo Nordisk INC | $392.86 | 2019-2024 | Wegovy |
| Bone Support INC. | $300.47 | 2022 | |
| Amgen INC. | $190.08 | 2020-2025 | Krystexxa |
| Glaxosmithkline, LLC. | $177.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $164.58 | 2019-2023 | Vaxelis, Gardasil 9, Vaxneuvance |
| Abbott Laboratories | $131.38 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.95 | 2020-2022 | |
| Astellas Pharma US INC | $100.12 | 2021-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.95 | 2019-2022 | |
| Allergan, INC. | $68.39 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $68.38 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $63.40 | 2024 | Gvoke Hypopen |
| Eisai INC. | $61.44 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $57.52 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $54.70 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.50 | 2021-2025 | |
| Ucb, INC. | $34.05 | 2019 | |
| Esperion Therapeutics, INC. | $33.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.15 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $23.97 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $23.88 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $18.80 | 2020 | |
| Dynavax Technologies Corporation | $15.73 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.36 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.29 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.58 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.